

STN	Biologické hodnotenie zdravotníckych pomôcok Časť 4: Výber skúšok na interakcie s krvou (ISO 10993-4: 2017)	STN EN ISO 10993-4 85 6513
------------	--	--

Biological evaluation of medical devices - Part 4: Selection of tests for interactions with blood (ISO 10993-4:2017)

Táto norma obsahuje anglickú verziu európskej normy.
This standard includes the English version of the European Standard.

Táto norma bola oznámená vo Vestníku ÚNMS SR č. 10/17

Obsahuje: EN ISO 10993-4:2017, ISO 10993-4:2017

Oznámením tejto normy sa ruší
STN EN ISO 10993-4 (85 6510) z októbra 2009

125432

Úrad pre normalizáciu, metrológiu a skúšobníctvo Slovenskej republiky, 2017
Podľa zákona č. 264/1999 Z. z. o technických požiadavkách na výrobky a o posudzovaní zhody a o zmene a doplnení niektorých zákonov v znení neskorších predpisov sa slovenská technická norma a časti slovenskej technickej normy môžu rozmnožovať alebo rozširovať len so súhlasom slovenského národného normalizačného orgánu.

EUROPEAN STANDARD
NORME EUROPÉENNE
EUROPÄISCHE NORM

EN ISO 10993-4

May 2017

ICS 11.100.20

Supersedes EN ISO 10993-4:2009

English Version

**Biological evaluation of medical devices - Part 4: Selection
of tests for interactions with blood (ISO 10993-4:2017)**

Évaluation biologique des dispositifs médicaux - Partie
4: Choix des essais pour les interactions avec le sang
(ISO 10993-4:2017)

Biologische Beurteilung von Medizinprodukten - Teil 4:
Auswahl von Prüfungen zur Wechselwirkung mit Blut
(ISO 10993-4:2017)

This European Standard was approved by CEN on 23 February 2017.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG

CEN-CENELEC Management Centre: Avenue Marnix 17, B-1000 Brussels

Contents	Page
European foreword.....	3
Annex ZA (informative) Relationship between this European Standard and the essential requirements of Directive 93/42/EEC [OJ L 169] aimed to be covered	4
Annex ZB (informative) Relationship between this European Standard and the essential requirements of Directive 90/385/EEC [OJ L 189] aimed to be covered.....	6

European foreword

This document (EN ISO 10993-4:2017) has been prepared by Technical Committee ISO/TC 194 “Biological and clinical evaluation of medical devices” in collaboration with Technical Committee CEN/TC 206 “Biological and clinical evaluation of medical devices” the secretariat of which is held by DIN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by November 2017, and conflicting national standards shall be withdrawn at the latest by November 2017.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN [and/or CENELEC] shall not be held responsible for identifying any or all such patent rights.

This document supersedes EN ISO 10993-4:2009.

This document has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association, and supports essential requirements of EU Directive(s).

For relationship with EU Directive(s), see informative Annex ZA and Annex ZB, which is an integral part of this document.

According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

Endorsement notice

The text of ISO 10993-4:2017 has been approved by CEN as EN ISO 10993-4:2017 without any modification.

Annex ZA (informative)

Relationship between this European Standard and the essential requirements of Directive 93/42/EEC [OJ L 169] aimed to be covered

This European Standard has been prepared under a Commission's joint standardization request M/BC/CEN/89/9 concerning harmonized standards relating to horizontal aspects in the field of medical devices to provide one voluntary means of conforming to essential requirements of Council Directive 93/42/EEC of 14 June 1993 concerning medical devices [OJ L 169].

Once this standard is cited in the Official Journal of the European Union under that Directive, compliance with the normative clauses of this standard given in Table ZA.1 confers, within the limits of the scope of this standard, a presumption of conformity with the corresponding essential requirements of that Directive and associated EFTA regulations.

NOTE 1 Where a reference from a clause of this standard to the risk management process is made, the risk management process needs to be in compliance with Directive 93/42/EEC as amended by 2007/47/EC. This means that risks have to be reduced 'as far as possible', 'to a minimum', 'to the lowest possible level', 'minimized' or 'removed', according to the wording of the corresponding essential requirement.

NOTE 2 The manufacturer's policy for determining acceptable risk must be in compliance with Essential Requirements 1, 2, 5, 6, 7, 8, 9, 11 and 12 of the Directive.

NOTE 3 This Annex ZA is based on normative references according to the table of references in the European foreword, replacing the references in the core text.

NOTE 4 When an Essential Requirement does not appear in Table ZA.1, it means that it is not addressed by this European Standard.

Table ZA.1 — Correspondence between this European Standard and Annex I of Directive 93/42/EEC [OJ L 169]

Essential Requirements of Directive 93/42/EEC	Clause(s)/subclause(s) of this EN	Remarks/Notes
7.1 (First indent)	6.1 and A.1, B.1, C.1, D.1 and E.1	ER 7.1 (first indent) is partly covered by ISO 10993-4, since the standard does not provide requirements on design and manufacture. However, this standard provides a means to evaluate the interactions of medical devices with blood. Other forms of toxicity and flammability are not dealt with in this standard.

7.1 (Second indent)	6.1 and A.1, B.1, C.1, D.1 and E.1	ER 7.1 (second indent) is partly covered by ISO 10993-4, since the standard does not provide requirements on design and manufacture. However, this standard provides a means to evaluate the interactions of medical devices with blood. Other forms of toxicity are not dealt with in this standard. This evaluation can be a preliminary step for risk minimization.
7.2	6.1 and A.1, B.1, C.1, D.1 and E.1	ER 7.2 is partly covered by ISO 10993-4, since the standard does not provide requirements on design, manufacture and packaging. However, this standard provides a means to assess the interactions of medical devices with blood to contaminants and residues in medical devices.
7.5	6.1 and A.1, B.1, C.1, D.1 and E.1	ER 7.5 is partly covered by ISO 10993-4, since the standard does not provide requirements on design and manufacture. However, this standard provides a means to evaluate interactions of substances leaking from medical devices with blood.

General Note: Presumption of conformity depends on also complying with all relevant clauses/subclauses of ISO 10993-1.

WARNING 1 — Presumption of conformity stays valid only as long as a reference to this European Standard is maintained in the list published in the Official Journal of the European Union. Users of this standard should consult frequently the latest list published in the Official Journal of the European Union.

WARNING 2 — Other Union legislation may be applicable to the products falling within the scope of this standard.

Annex ZB (informative)

Relationship between this European Standard and the essential requirements of Directive 90/385/EEC [OJ L 189] aimed to be covered

This European Standard has been prepared under a Commission's joint standardization request M/BC/CEN/89/9 concerning harmonized standards relating to horizontal aspects in the field of medical devices to provide one voluntary means of conforming to essential requirements of Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of the Member States relating to active implantable medical devices [OJ L 189].

Once this standard is cited in the Official Journal of the European Union under that Directive, compliance with the normative clauses of this standard given in Table ZB.1 confers, within the limits of the scope of this standard, a presumption of conformity with the corresponding essential requirements of that Directive and associated EFTA regulations.

NOTE 1 Where a reference from a clause of this standard to the risk management process is made, the risk management process needs to be in compliance with Directive 90/385/EEC as amended by 2007/47/EC. This means that risks have to be reduced 'as far as possible', 'to a minimum', 'to the lowest possible level', 'minimized' or 'removed', according to the wording of the corresponding essential requirement.

NOTE 2 The manufacturer's policy for determining acceptable risk must be in compliance with Essential Requirements 1, 4, 5, 8, 9 and 10 of the Directive.

NOTE 3 This Annex ZB is based on normative references according to the table of references in the European foreword, replacing the references in the core text.

NOTE 4 When an Essential Requirement does not appear in Table ZB.1, it means that it is not addressed by this European Standard.

Table ZB.1 — Correspondence between this European Standard and Annex I of Directive 90/385/EEC [OJ L 189]

Essential Requirements of Directive 90/385/EEC	Clause(s)/subclause(s) of this EN	Remarks/Notes
9 (first indent)	6.1 and A.1, B.1, C.1, D.1 and E.1	ER 9 (first indent) is partly covered by ISO 10993-4, since the standard does not provide requirements on design and manufacture. These haemocompatibility tests are not intended to evaluate or determine the performance of the test sample in terms of mechanical or functional loading. However, this part of ISO 10993 specifies test methods for the assessment of the interaction with blood with medical devices or biomaterials intended for use in medical devices. Other forms of toxicity are

		not dealt with in this standard.
9 (second indent)	6.1 and A.1, B.1, C.1, D.1 and E.1	ER 9 (second indent) is partly covered by ISO 10993-4, since the standard does not provide requirements on design and manufacture. However, this standard provides a means to evaluate the interactions of medical devices with blood. Other forms of toxicity are not dealt with in this standard.

General Note: Presumption of conformity depends on also complying with all relevant clauses/subclauses of ISO 10993-1.

WARNING 1 — Presumption of conformity stays valid only as long as a reference to this European Standard is maintained in the list published in the Official Journal of the European Union. Users of this standard should consult frequently the latest list published in the Official Journal of the European Union.

WARNING 2 — Other Union legislation may be applicable to the products falling within the scope of this standard.

Biological evaluation of medical devices —

Part 4: Selection of tests for interactions with blood

Évaluation biologique des dispositifs médicaux —

Partie 4: Choix des essais pour les interactions avec le sang





COPYRIGHT PROTECTED DOCUMENT

© ISO 2017, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Ch. de Blandonnet 8 • CP 401
CH-1214 Vernier, Geneva, Switzerland
Tel. +41 22 749 01 11
Fax +41 22 749 09 47
copyright@iso.org
www.iso.org

Contents

Page

Foreword	iv
Introduction	vi
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 Abbreviated terms	4
5 Types of devices in contact with blood (as categorized in ISO 10993-1)	5
5.1 Non-blood-contact devices.....	5
5.2 External communicating devices.....	5
5.2.1 General.....	5
5.2.2 External communicating devices that serve as an indirect blood path.....	5
5.2.3 External communicating devices directly contacting circulating blood.....	5
5.3 Implant devices.....	6
6 Characterization of blood interactions	6
6.1 General requirements.....	6
6.2 Categories of tests and blood interactions.....	12
6.2.1 Recommended tests for interactions of devices with blood.....	12
6.2.2 Non-contact devices.....	13
6.2.3 External communicating devices and implant devices.....	13
6.2.4 Limitations.....	13
6.3 Types of tests.....	13
6.3.1 <i>In vitro</i> tests.....	13
6.3.2 <i>Ex vivo</i> tests.....	14
6.3.3 <i>In vivo</i> tests.....	14
Annex A (informative) Preclinical evaluation of cardiovascular devices and prostheses	16
Annex B (informative) Recommended laboratory tests — Principles, scientific basis and interpretation	21
Annex C (informative) Thrombosis — Methods for <i>in vivo</i> testing	32
Annex D (informative) Haematology/haemolysis — Methods for testing — Evaluation of haemolytic properties of medical devices and medical device materials	39
Annex E (informative) Complement — Methods for testing	46
Annex F (informative) Less common laboratory tests	49
Annex G (informative) Tests which are not recommended	53
Bibliography	55

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 194, *Biological and clinical evaluation of medical devices*.

This third edition cancels and replaces the second edition (ISO 10993-4:2002), which has been technically revised.

It also incorporates the Amendment ISO 10993-4:2002/Amd 1:2006.

The following changes were made:

- a) some definitions have been revised and new definitions have been added;
- b) Tables 1 and 2 have been consolidated into a single new [Table 1](#) with test categories and headers reorganized to emphasize and include material and mechanical-induced haemolysis testing and *in vitro* and *in vivo* testing for assessment of risk for thrombosis;
- c) Tables 3 and 4 have been consolidated into a single new [Table 2](#) with a simplified list of suggested and most common tests;
- d) [Annex B](#) has been updated to cover only the most common practiced tests for assessing blood interactions;
- e) [Annex C](#) has been added to cover the topic of *in vivo* thrombosis and methods for testing;
- f) [Annex D](#), which was Annex C in the previous edition, has been updated and now includes added information on mechanically-induced haemolysis;
- g) [Annex E](#) has been added to cover the topic of complement testing and best test method practices;
- h) [Annexes F](#) and [G](#) have been added to present the less common tests used to assess interactions with blood and the tests that are not recommended for preclinical assessment of medical device blood interaction, respectively. Many of these methods were previously included in [Annex B](#);

- i) subtle language refinements can be found throughout the revised document;
- j) the Bibliography has been reorganized by common subjects of interest and updated with additional and more current references.

Introduction

The selection and design of test methods for the interactions of medical devices with blood should take into consideration device design, materials, clinical utility, usage environment and risk benefit. This level of specificity can only be covered in vertical standards.

The initial source for developing this document was the publication, *Guidelines for blood/material interactions*, Report of the National Heart, Lung, and Blood Institute^[14] chapters 9 and 10. This publication was subsequently revised^[15].

Biological evaluation of medical devices —

Part 4: Selection of tests for interactions with blood

1 Scope

This document specifies general requirements for evaluating the interactions of medical devices with blood.

It describes

- a) a classification of medical devices that are intended for use in contact with blood, based on the intended use and duration of contact as defined in ISO 10993-1,
- b) the fundamental principles governing the evaluation of the interaction of devices with blood,
- c) the rationale for structured selection of tests according to specific categories, together with the principles and scientific basis of these tests.

Detailed requirements for testing cannot be specified because of limitations in the knowledge and precision of tests for evaluating interactions of devices with blood. This document describes biological evaluation in general terms and may not necessarily provide sufficient guidance for test methods for a specific device.

The changes in this document do not indicate that testing conducted according to prior versions of this document is invalid. For marketed devices with a history of safe clinical use, additional testing according to this revision is not recommended.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993-1, *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process*

ISO 10993-12, *Biological evaluation of medical devices — Part 12: Sample preparation and reference materials*

koniec náhľadu – text ďalej pokračuje v platenej verzii STN